GSK, Spero reveal full Phase 3 data for oral antibiotic, set for end-of-year...
GSK and Spero Therapeutics are taking their oral antibiotic to the FDA after reporting the full Phase 3 non-inferiority data. The companies said Monday that tebipenem HBr performed no worse than ...
View ArticleNeuphoria scraps social anxiety drug; Minerva doubles down on schizophrenia...
Plus, news about Syncona, Ventus Therapeutics, Roche, Disc Medicine, Atai Life Sciences, Lexeo Therapeutics, Novartis, Vivace Therapeutics, Kura Oncology, Corbus and J&J: 💼 Neuphoria Therapeutics’...
View ArticleAs China moves beyond ‘me-too,’ do Western regulators need to reconsider?
BERLIN — At Europe’s largest cancer conference, Sunday's main stage belonged to China. Medical conferences use their keynote sessions to highlight results from what the top researchers in the world...
View ArticleRegeneron reaches patent deal with Celltrion over Eylea biosimilar
Celltrion can sell a biosimilar version of Regeneron’s Eylea in the US at the end of 2026, following a patent deal between the two companies that also clears the path for more competition against the ...
View ArticleCuban's Cost Plus links with White House's TrumpRx site
Billionaire entrepreneur Mark Cuban and his heavily discounted, mostly generic drug online pharmacy will link up with President Donald Trump's incoming online marketplace TrumpRx, aiming to connect...
View ArticleGrail raises $325M from Hims and others ahead of FDA bid
Grail has raised $325 million in a private placement, bolstering the company's balance sheet as it prepares to ask the FDA to approve its blood test that's designed to detect dozens of cancers. The...
View ArticleFirst impressions on the ground at HLTH 2025
Hi from Las Vegas! Ngai and I have made it through two days of HLTH, our heads are hurting from all the conversations we’ve had, and our notebooks are full. I figured I’d save some ...
View ArticleElevara raises $70M to test a breast cancer approach in rheumatoid arthritis
A London-based biotech has secured $70 million to study its CDK4/6 inhibitor — a mechanism primarily used to treat breast cancer — in rheumatoid arthritis. Elevara Medicines emerged from stealth on...
View ArticleGenmab was one of three bidders before inking $8B Merus acquisition
There were multiple bidders at the table for the fourth-largest biopharma acquisition of 2025, according to a regulatory filing, bucking the trend of single-suitor processes for many other deals this...
View ArticlePolaris Partners plans to raise $500M for latest biotech fund
Polaris Partners, a long-time biotech investor that has backed more than 400 companies, is looking to raise as much as $500 million for its Fund XI, according to an SEC
View Article10x Genomics files patent suits against Illumina
10x Genomics on Tuesday filed two lawsuits against Illumina, alleging the DNA sequencing giant infringed patents as part of a push to broaden its offerings. Both cases were filed in Delaware federal ...
View ArticleTakeda makes major bispecific, ADC pact with Innovent for $1.2B upfront
Takeda, which is undergoing a big pipeline transformation, has forged one of the year's largest upfront R&D pacts. And like more than a third of this year's biopharma licensing deals, it involves a...
View ArticleIpsen to buy ImCheck for €350M to get 'superfamily' of immunotherapies
Ipsen will buy fellow French biotech ImCheck Therapeutics for €350 million upfront ($406 million), adding to a series of M&A deals that have steadily buoyed the industry's optimism in recent weeks....
View ArticleFlagship debuts AI biotech startup Expedition with $50M
Since co-founding Generate:Biomedicines in 2018, Molly Gibson says the bar has gone up for building AI-focused biotech startups, courtesy of the rapid progress in applying AI to biology. Gibson...
View ArticleSanofi backs immunology startup, which raises $183M Series C for lead drug's...
An immunology startup has a hefty round of cash to get its lead program through a pivotal study and advance another preclinical drug into human testing. Electra Therapeutics on Wednesday closed a $183...
View ArticleAlector’s GSK-partnered dementia drug flunks Phase 3, plots to halve workforce
Alector said one antibody from its $700 million upfront deal with GSK missed a key endpoint in a Phase 3 study in dementia. The biotech will end work on that asset and ...
View ArticleSanofi reveals Phase 2 rare disease win from Inhibrx buyout
Sanofi on Wednesday reported a successful Phase 2 result for the rare disease drug it acquired in its buyout of Inhibrx last year. The program, called efdoralprin alfa and formerly known as INBRX-101,...
View ArticleSummit raises $500M, with more than half coming from its C-suite
Summit Therapeutics announced a $500 million private placement on Wednesday, more than half of which comes from members of its C-suite. The company’s billionaire co-CEO Bob Duggan, along with co-CEO...
View ArticleJapan’s Fast Track Initiative announces new $130M venture fund
Japanese venture firm Fast Track Initiative on Tuesday unveiled its fourth fund of about $130 million, or ¥20 billion. The firm is riding a wave of interest since Shimon Sakaguchi — the founder of one...
View ArticleStarna Therapeutics raises $44M to advance in vivo CAR-T programs after early...
The global race to develop in vivo CAR-T therapies that could replace onerous cell therapies with simpler, safer infusions continues to heat up, and now a Chinese biotech startup has quietly begun...
View Article